Financing ·
Lantern Pharma raises $4 million in registered direct offering and concurrent private placement at $1.09 per share
LTRNLantern Pharma Inc.
Lantern Pharma Inc. closed a registered direct offering and concurrent private placement on September 30, 2026, raising approximately $4 million in gross proceeds. The company issued 1,469,725 shares of common stock at $1.09 per share and pre-funded warrants for up to 2,200,000 additional shares at $1.0899 each. Concurrently, it sold unregistered warrants to purchase up to 3,669,725 shares at an exercise price of $1.09 per share in a private placement under Regulation D. Rodman & Renshaw LLC acted as the sole placement agent, receiving a 7% cash fee and warrants for 5% of the common shares sold. The unregistered warrants require stockholder approval to be exercisable, which the company must seek within 90 days. Lantern Pharma is a clinical-stage biopharmaceutical company leveraging artificial intelligence to develop precision oncology therapies.